Skip to main content

Table 2 Primary and secondary outcomes of the included trials: PCT arms versus control arms

From: Procalcitonin-guided antibiotic therapy in critically ill adults: a meta-analysis

Study (year)

Primary endpoints

Second endpoints

28-day mortality

duration of antibiotic therap by for the first episode of infectiona

length of hospitalizationa

mortality in hospitalization

total duration of antibiotic therapy a

length of ICU stay a

Recurrences

Svoboda (2007) [33]

10/13

NA

NA

NA

NA

16.1 (6.9) /19.4 (8.9)

NA

Nobre (2008) [32]

8/8

6.0 (7.8) /9.5 (7.8)

17.0 (23.3) /23.5 (9.8)

9/9/

8.0 (5.8) /14.0 (8.3)

4.0 (5.0) /7.0 (22.5)

1/1/

Hochreiter (2009) [31]

NA

5.9 (1.7) /7.9 (0.5)

NA

15/14

5.9 (1.7) /7.9 (0.5)

15.5 (12.5) /17.7 (10.1)

NA

Schroeder (2009) [30]

NA

6.6 (1.1) /8.3 (0.7)

NA

3/3

6.6 (1.1) /8.3 (0.8)

16.4 (8.3) /16.7 (5.6)

NA

Stolz (2009) [29]

8/12

3.0 (2.0) /5.0 (4.1)

26.0 (10.4) /26.0 (4.1)

10/14

10.0 (2.5) /15.0 (3.3)

NA

6/11

Bouadma (2010) [28]

65/64

6.1 (6.0) /9.9 (7.1)

26.1 (19.3) /26.4 (18.3)

NA

10.3 (7.7) /13.3 (7.6)

15.9 (16.1) /14.4 (4.1)

20/16

Layios (2012) [26]

56/53

NA

NA

NA

NA

7.0 (8.9) /7.0 (10.4)

NA

Jensen (2011) [27]

190/191

NA

NA

NA

NA

6.0 (6.7) /5.0 (5.9)

NA

Liu (2013) [23]

6/5

8.1 (0.3) /9.3 (0.3)

27.0 (4.9) /32.0 (5.4)

NA

8.1 (0.3) /9.3 (0.3)

12.0 (2.9) /14.0 (2.7)

3/1

Annane (2013) [25]

NA

NA

27.0 (29.6) /33.0 (43.0)

7/10

NA

22.0 (25.2) /23.0 (37.0)

NA

Deliberato (2013) [24]

NA

NA

11.0 (11) /11.0 (56.5)

2/4

NA

3.5 (14.0) /3.0 (6.8)

2/1

Shehabi (2014) [22]

21/15

NA

15.0 (14.8) /17.0 (16.3)

30/26

NA

6.0 (4.8) /6.0 (4.4)

6/12

Najafi (2015) [21]

NA

NA

20.0 (9.0) /22.0 (14.8)

5/4

NA

4.0 (4.5) /6.0 (6.5)

NA

Jong (2016) [18]

149/196

NA

22.0 (19.3) /22.0 (20.7)

NA

NA

8.5 (8.9) /9.0 (9.6)

38/23

Bloos (2016) [20]

77/60

7.0 (6.7) /7.0 (7.4)

29.0 (23.7) /29.0 (24.4)

NA

NA

12.0 (14.1) /12.0 (11.1)

NA

  1. aMean (SD); NA, not available